BioAge Labs

Yahoo Finance • 3 days ago

BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)

BioAge Labs Inc. (NASDAQ:BIOA) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 10, Citi maintained a Buy rating on BioAge Labs Inc. (NASDAQ:BIOA). The firm significantly increased its pri... Full story

Yahoo Finance • 9 days ago

BioAge Labs GAAP EPS of -$2.24 beats by $0.08, revenue of $8.99M beats by $1.88M

* BioAge Labs press release [https://seekingalpha.com/pr/20448840-bioage-labs-reports-full-year-2025-financial-results-and-provides-business-updates-from-the] (BIOA [https://seekingalpha.com/symbol/BIOA]): FY GAAP EPS of -$2.24 beats by... Full story

Yahoo Finance • last month

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 4 months ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 5 months ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 6 months ago

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenanc... Full story

Yahoo Finance • 6 months ago

BioAge Labs files $250M mixed securities shelf

* BioAge Labs (NASDAQ:BIOA [https://seekingalpha.com/symbol/BIOA]) files $250M mixed securities shelf. * This prospectus is not an offer to sell these securities. * Filing [https://seekingalpha.com/filing/10487765] MORE ON * Powe... Full story

Yahoo Finance • 6 months ago

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of lon... Full story

Yahoo Finance • 6 months ago

Leqembi® approved for IV maintenance treatment in China

STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treat... Full story

Yahoo Finance • 6 months ago

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients wi... Full story

Yahoo Finance • 7 months ago

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

BioArctic has seen a significant price movement of 41% over the past quarter. This surge is closely tied to several positive developments, including an impressive earnings report where the company posted a net income of SEK 96 million, rev... Full story

Yahoo Finance • 7 months ago

BioArctic signs $30 million deal with Novartis for brain drug delivery tech

STOCKHOLM - BioArctic AB (Nasdaq Stockholm:BIOA B), a pharmaceutical company with a market capitalization of $44.9 billion and an "GREAT" financial health rating according to InvestingPro, has entered into an option, collaboration and lice... Full story

Yahoo Finance • 7 months ago

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new trea... Full story

Yahoo Finance • 7 months ago

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 8 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated... Full story

Yahoo Finance • 8 months ago

Peptide Synthesis Company Evaluation Report 2025 | Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies Lead with Advanced Instruments, Reagents, and Strategic Expansions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Peptide Synthesis Company Evaluation Report" report has been added to ResearchAndMarkets.com's offering. The Peptide Synthesis Market Companies Quadrant is a comprehensive industry analy... Full story

Yahoo Finance • 9 months ago

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders... Full story

Yahoo Finance • 9 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for... Full story

Yahoo Finance • 11 months ago

Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, April 22, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) If you have held BioAge Labs, Inc. (NASDAQ: BIOA) shares continuously since on or shortly after its September 26, 2024 IPO, you can seek corporate reform... Full story

Yahoo Finance • 12 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)

PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) If you have held BioAge Labs, Inc. (NASDAQ: BIOA) shares continuously since on or shortly after its September 26, 2024 IPO, you can seek corporate reform... Full story